OTC薬(一般用医薬品)の世界市場2016-2020

◆英語タイトル:Global Over-the-Counter Drug Market 2016-2020
◆商品コード:IRTNTR10079
◆発行会社(調査会社):Technavio
◆発行日:2016年8月12日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、OTC薬(一般用医薬品)の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、OTC薬(一般用医薬品)の世界市場規模及び予測、種類別分析、治療クラス別分析、投与経路(ROA)別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About OTC Drugs
OTC drugs are medicines that can be bought without a prescription from a doctor because the US FDA considers them safe for use without medical supervision. These drugs are used to treat conditions that do not necessarily require a doctor’s advice, such as pain, itches, cough and cold, sleeping problems, smoking cessation, weight problems, gastrointestinal problems, and tooth decay. They are sold through hospitals, pharmaceutical stores, grocery stores, catalogs, and online retail stores.

Technavio’s analysts forecast the global over-the-counter (OTC) drug market to grow at a CAGR of 6.19% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global over-the-counter (OTC) drug market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of OTC drugs used to treat disorders, including gastrointestinal disorders, pain, and dermatological and respiratory disorders.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Over-The-Counter (OTC) Drug Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer HealthCare
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Pfizer
• Sanofi

[Other prominent vendors]
• Abbott
• Achelios Therapeutics
• American Health
• Amgen
• Arena Pharmaceuticals
• AstraZeneca
• BioGaia
• Bristol Myers Squibb
• Bukwang Pharmaceutica
• Chr. Hansen
• Cipla
• CoLucid
• Daiichi Sankyo
• Dr. Reddy’s Laboratories
• DSM
• Eisai
• Eli Lilly
• EMS
• Euradite
• Friggs
• Genomma Lab Internacional
• Glanbia
• Herbalife
• Himalaya Drug Company
• Hypermarcas
• Immune Pharmaceuticals
• Innovative Med Concepts
• Mcneil consumer healthcare
• Mead Johnson
• Merck
• Mitsubishi Tanabe Pharma
• NeurAxon
• Omega Pharma
• OptiNose
• Pain Therapeutics
• Procter & Gamble
• Reckitt Benckiser
• SAVA
• Sigma Pharmaceuticals
• Sun Pharma
• Taisho Pharmaceuticals
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• UCB
• Unifarma Global Consumer healthcare
• Valeant Pharmaceuticals
• Vida Laboratories

[Market driver]
• Switching of medications from prescription to OTC
• For a full, detailed list, view our report

[Market challenge]
• Counterfeit drugs
• For a full, detailed list, view our report

[Market trend]
• Accelerated use of online resources
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: OTC drugs: An overview
• Regulatory pathways for OTC approval
• FDA OTC drug approval process
• Strategies to penetrate OTC pharmaceuticals in emerging markets

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by therapeutic class

PART 08: Global respiratory OTC drugs market
• Market overview

PART 09: Global dietary supplements market
• Market overview

PART 10: Global gastrointestinal OTC drugs market
• Market overview
• Market segmentation by therapeutic class of drug

PART 11: Global OTC pain medications market
• Market overview
• Market segmentation by therapeutic class of drug

PART 12: Market segmentation by route of administration
• Oral
• Topical
• Parenteral

PART 13: Geographical segmentation
• Global OTC drugs market by geography 2015-2020
• OTC drugs market in Americas
• OTC drugs market in US
• OTC drugs market in EMEA
• OTC drugs market in Germany
• OTC drugs market in France
• OTC drugs market in APAC
• OTC drugs market in China
• OTC drugs market in Japan
• OTC drugs market in India

PART 14: Market drivers
• Switching of medications from prescription to OTC
• Lenient regulatory framework and distribution channel
• Cost-effective OTC drugs
• Rise in self-medication

PART 15: Impact of drivers

PART 16: Market challenges
• Counterfeit drugs
• Lack of valid literature
• High expenditure on advertisements

PART 17: Impact of drivers and challenges

PART 18: Market trends
• Accelerated use of online resources
• Promotions and marketing initiatives
• Strategic alliances

PART 19: Vendor landscape
• Competitive scenario

PART 20: Key vendor analysis
• GSK
• Johnson & Johnson
• Pfizer
• Bayer HealthCare
• Sanofi3
• Other prominent vendors

PART 21: Appendix6
• List of abbreviations

PART 22: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of OTC drugs market
Exhibit 03: Comparison between prescription and OTC drugs
Exhibit 04: Advantages and disadvantages of OTC drugs
Exhibit 05: Key regulatory bodies for OTC approval
Exhibit 06: FDA OTC drug approval process
Exhibit 07: Mechanisms to amend OTC drug monograph
Exhibit 08: Comparison of OTC NDA and OTC monograph process
Exhibit 09: Strategies to establish OTC pharmaceuticals in emerging markets
Exhibit 10: Strategies to establish OTC pharmaceuticals in established markets
Exhibit 11: Global OTC drugs market 2015-2020 ($ billions)
Exhibit 12: Few prescription to OTC switches before the expiry of patents
Exhibit 13: Growth potential of various therapy areas in OTC market
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of global OTC pharmaceuticals by therapeutic class
Exhibit 16: Segmentation of global OTC pharmaceuticals market by therapeutic class 2015
Exhibit 17: Global OTC market segmentation: Growth cycle analysis
Exhibit 18: List of drugs that underwent Rx-to-OTC switch
Exhibit 19: OTC medications for upper respiratory infections
Exhibit 20: Global respiratory OTC drugs market 2015-2020 ($ billions)
Exhibit 21: Recommendation of dietary supplements by health professionals
Exhibit 22: Global dietary supplements market 2015-2020 ($ billions)
Exhibit 23: Drugs underwent Rx-to-OTC switch in US
Exhibit 24: Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
Exhibit 25: Global OTC pain medications market 2015-2020 ($ billions)
Exhibit 26: Global OTC analgesics market by therapeutic class of drug 2015
Exhibit 27: Segmentation of global OTC drugs market by route of administration 2015
Exhibit 28: Global OTC drugs market by geography 2015-2020
Exhibit 29: Percentage share of global OTC drugs market by geography 2015 and 2020
Exhibit 30: Global OTC drugs market segmentation by geography 2015-2020 ($ billions)
Exhibit 31: Global share of OTC drugs market by geography 2015
Exhibit 32: Global OTC drugs market: Country analysis based on revenue and growth rate
Exhibit 33: OTC drugs market in Americas 2015-2020 ($ billions)
Exhibit 34: Major attributes of OTC medicines
Exhibit 35: OTC drugs market in US 2015-2020 ($ billions)
Exhibit 36: OTC drugs market in EMEA 2015-2020 ($ billions)
Exhibit 37: OTC market in EMEA: Short term versus long term 2015-2017
Exhibit 38: Distribution channels of key countries in Europe
Exhibit 39: Percentage share of Europe and MEA in OTC drugs market in EMEA 2015
Exhibit 40: Snapshot of OTC market in Germany
Exhibit 41: Distribution system of OTC drugs market in Germany
Exhibit 42: YoY OTC drug revenues from distribution chains in Germany 2014-2015 ($ millions)
Exhibit 43: OTC drugs market in Germany 2015-2020 ($ billions)
Exhibit 44: Key takeaways from market dynamics of European countries 2015-2017
Exhibit 45: OTC drugs market in France 2015-2020 ($ billions)
Exhibit 46: OTC drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: OTC drugs market in China 2015-2020 ($ billions)
Exhibit 48: OTC drugs market in Japan 2015-2020 ($ billions)
Exhibit 49: Growth factors of OTC market in India
Exhibit 50: OTC drugs market in India 2015-2020 ($ billions)
Exhibit 51: Factors promoting and inhibiting switch of Rx to OTC
Exhibit 52: Rx to OTC switch in US 2011-2015
Exhibit 53: Potential future candidates for OTC medications
Exhibit 54: Saving made by swapping branded for non-prescription generics for few drugs
Exhibit 55: Impact of drivers
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Promotional activities during various stages of OTC product lifecycle
Exhibit 58: Presence of vendors in different therapy areas in OTC drugs market
Exhibit 59: Geographical presence of key vendors in OTC drugs market 2015
Exhibit 60: Competitive scenario of global OTC drugs market vendors 2015-2020
Exhibit 61: Market share of key vendors based on revenue 2015
Exhibit 62: GSK: Product category (consumer healthcare) by revenue 2013-2015
Exhibit 63: GSK: YoY revenue and growth rate of wellness products 2013-2015 ($ billions)
Exhibit 64: GSK: YoY revenue and growth rate of skin health products 2013-2015 ($ millions)
Exhibit 65: GSK: Geographical segmentation by revenue (consumer health) 2015
Exhibit 66: GSK: Metrics analysis
Exhibit 67: Johnson & Johnson: Product category (consumer healthcare) by revenue 2014
Exhibit 68: Johnson & Johnson: Revenue and growth rate of OTC products 2013-2015 ($ billions)
Exhibit 69: Johnson & Johnson: Geographical segmentation by revenue (consumer healthcare) 2015
Exhibit 70: Johnson & Johnson: Metrics analysis
Exhibit 71: Pfizer: YoY revenue and growth rate of OTC drugs 2013-2015 ($ billions)
Exhibit 72: Pfizer: Metrics analysis
Exhibit 73: Bayer HealthCare: Consumer health segmentation by revenue 2015
Exhibit 74: Bayer HealthCare: Geographic segmentation of consumer healthcare segment 2015
Exhibit 75: Bayer HealthCare: YoY revenue and growth rate of Aspirin 2013-2015 ($ millions)
Exhibit 76: Bayer HealthCare: YoY revenue and growth rate of Aleve 2013-2015 ($ millions)
Exhibit 77: Bayer HealthCare: YoY revenue and growth rate of Bepanthen/Bepanthol 2013-2015 ($ millions)
Exhibit 78: Bayer HealthCare: YoY revenue and growth rate of Canesten 2013-2015 ($ millions)
Exhibit 79: Bayer HealthCare: Metrics analysis
Exhibit 80: Sanofi: Geographical segmentation by revenue 2015 (consumer healthcare)
Exhibit 81: Sanofi: YoY revenue and growth rate of Allegra 2013-2015 ($ millions)
Exhibit 82: Sanofi: YoY revenue and growth rate of Doliprane 2013-2015 ($ millions)
Exhibit 83: Sanofi: YoY revenue and growth rate of Essentiale 2012-2014 ($ million)
Exhibit 84: Sanofi: YoY revenue and growth rate of Enterogermina 2013-2015 ($ millions)
Exhibit 85: Sanofi: YoY revenue comparison of Nasacort 2014-2015 ($ millions)
Exhibit 86: Sanofi: YoY revenue and growth rate of Buscopan 2013-2015 ($ millions)
Exhibit 87: Sanofi: YoY revenue and growth rate of Dulcolax 2013-2015 ($ millions)
Exhibit 88: Sanofi: YoY revenue and growth rate of Mucosolvan 2013-2015 ($ millions)
Exhibit 89: Sanofi: YoY revenue and growth rate of Pharmaton 2013-2015 ($ millions)
Exhibit 90: Sanofi: Metrics analysis



【掲載企業】

GSK, Johnson & Johnson, Pfizer, Bayer HealthCare, Sanofi, Abbott, Achelios Therapeutics, American Health, Amgen, Arena Pharmaceuticals, AstraZeneca, BioGaia, Bristol Myers Squibb, Bukwang Pharmaceutica, Chr. Hansen, Cipla, CoLucid, Daiichi Sankyo, Dr. Reddy's Laboratories, DSM, Eisai, Eli Lilly, EMS, Euradite, Friggs, Genomma Lab Internacional, Glanbia, Herbalife, Himalaya Drug Company, Hypermarcas, Immune Pharmaceuticals, Innovative Med Concepts, Mcneil consumer healthcare, Mead Johnson, Merck, Mitsubishi Tanabe Pharma, NeurAxon, Omega Pharma, OptiNose¸ Pain Therapeutics, Procter & Gamble, Reckitt Benckiser, SAVA, Sigma Pharmaceuticals, Sun Pharma, Taisho Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceuticals, UCB, Unifarma Global Consumer healthcare, Valeant Pharmaceuticals, Vida Laboratories.

【レポートのキーワード】

OTC薬、一般用医薬品、大衆薬、治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[OTC薬(一般用医薬品)の世界市場2016-2020]販売に関する免責事項
★調査レポート[OTC薬(一般用医薬品)の世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆